Stock comparison
Boston Scientific
BSX$74.52BHealthcare Market cap, Sector
Pro Medicus Limited
PME.AX$18.98BHealthcare Market cap, Sector
Overall winner
Pro Medicus Limited
BSX 07 PME.AX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
BSX0wins
7winsPME.AX
59D
B78
64C
A90
67C
A98
55D
A100
40F
B84
52D
A91
56D
A96
Side-by-side metrics
| Metric | BSX | PME.AX |
|---|---|---|
| Market cap | Winner: $74.52B | $18.98B |
| P/E (TTM) | Winner: 20.2x | 147.6x |
| EV/EBIT | Winner: 20.5x | 106.8x |
| ROIC (TTM) | 9.9% | 42.56% Winner |
| Gross margin | 70.41% | 99.85% Winner |
| Net margin | 17.24% | 54.12% Winner |
| Revenue CAGR 5y | 13.99% | 31.61% Winner |
| EPS CAGR 5y | 29.71% | 37.34% Winner |
| Debt / Equity | 0.4x | 0.0x Winner |
| Dividend yield | 0.0% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BSX leads on
- P/E (TTM)20.2xvs 147.6x+86%
- EV/EBIT20.5xvs 106.8x+81%
- Market cap$74.52Bvs $18.98B+75%
PME.AX leads on
- Debt / Equity0.0xvs 0.4x+98%
- ROIC (TTM)42.56%vs 9.9%+77%
- Net margin54.12%vs 17.24%+68%
- Revenue CAGR 5y31.61%vs 13.99%+56%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.